Pemigatinib in the Advanced Gastrointestinal Cancer With FGFR 1-3 Alterations

Sponsor
Tianjin Medical University Cancer Institute and Hospital
Study ID
NCT05651672
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Gastrointestinal Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Pemigatinib — DRUG
    13.5mg, po, 2 weeks on/1 week off, Q3W

Study Details

This study is a prospective single-arm phase II study to evaluate the efficacy and safety of Pemigatinib in the advanced gastrointestinal cancer with FGFR 1-3 alterations and failed standard therapy.

Key Dates

First listed
Dec 15, 2022
Start date
Dec 2, 2022
Status verified
Dec 2022
Primary completion
Dec 31, 2024
Completion
Dec 31, 2026

Study Design

Enrollment
100 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: experimental group
    Pemigatinib

Primary Outcome Measure

Overall response rate (ORR) [ Time Frame: up to 2 years ]

Central Contacts

Related Studies